Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of tandutinib and to see how
well it works in treating patients with recurrent or progressive glioblastoma.Tandutinib may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by
blocking blood flow to the tumor.